Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06897930 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

A Phase 1 study of Lupus Erythematosus, Systemic, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
150
Enrollment target
16
Study locations

NCT06897930 is a Phase 1 study of Lupus Erythematosus, Systemic that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 150 participants, below the 198-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (24% lower). The trial reports 16 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06897930, a Phase 1 study of Lupus Erythematosus, Systemic, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
150 participants
Enrollment target
16
Study locations

Study Summary

This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.

Conditions Studied

Lupus Erythematosus, Systemic

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • BIOLOGICAL AZD0120

Study Locations (16)

California

  • Research Site - San Francisco
  • Research Site - Stanford

New York

  • Research Site - New York
  • Research Site - Syracuse

North Carolina

  • Research Site - Chapel Hill
  • Research Site - Charlotte

Washington

  • Research Site - Seattle
  • Research Site - Seattle

Other

  • Research Site - Darlinghurst
  • Research Site - Melbourne

Florida

  • Research Site - Tampa

Georgia

  • Research Site - Atlanta

Maryland

  • Research Site - Bethesda

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2025-04-21
Est. Completion 2029-05-01
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06897930

The ClinicalTrials.gov registry entry for NCT06897930 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (24% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.

NCT06897930 reports 16 study locations spanning 11 distinct geographic areas - top geographies include California, New York, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06897930 about?

NCT06897930 is a clinical study titled "A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE". This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.

What is the current status of trial NCT06897930?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2025-04-21. Estimated completion is 2029-05-01.

What conditions does trial NCT06897930 study?

This clinical trial studies the following conditions: Lupus Erythematosus, Systemic.

What interventions are being tested in trial NCT06897930?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), AZD0120 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06897930?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06897930 being conducted?

This trial has 16 study locations across California, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lupus Erythematosus, Systemic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lupus Erythematosus, Systemic

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.